Sponsor Study ID:
A Phase II/III Study of Peri operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
(MUSC NetID required for document access)